Tolerability of atorvastatin in a population aged ≥65 years: A retrospective pooled analysis of results from fifty randomized clinical trials

American Journal Geriatric Pharmacotherapy

Volumn 4, Issue 2, 2006, Pages 112-122

  Hey Hadavi, Judith H ^a   Kuntze, Erik ^a   Luo, Don ^a   Silverman, Paul ^a   Pittman, Donald ^a   LePetri, Barbara ^a  

^a PFIZER INC   (United States)

Author keywords

atorvastatin; coronary heart disease; elderly; safety

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CLOPIDOGREL; CREATINE KINASE; PLACEBO; VERAPAMIL; WARFARIN;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMINURIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLECYSTITIS; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DATA BASE; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HEMATURIA; HEPATITIS B; HUMAN; INFORMATION RETRIEVAL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; METABOLIC DISORDER; MICROALBUMINURIA; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NEPHROTOXICITY; NEUROTOXICITY; NUTRITIONAL DISORDER; OBSTRUCTIVE JAUNDICE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SKIN TOXICITY; UROGENITAL TRACT DISEASE;

AGED; ANTICHOLESTEREMIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; KIDNEY DISEASES; LIVER DISEASES; MALE; MUSCULOSKELETAL DISEASES; PYRROLES; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 33746076715     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2006.06.001     Document Type: Article

References (42)

1. [NHANES 19992002] [CDC Web site]. Available at:. Centers for Disease Control and Prevention (CDC)/ National Center for Health Statistics. National Health and Nutrition Examination Survey. Accessed (March 9, 2006). http://www.cdc.gov/nchs/about/major/nhanes/hlthprofess.htm
2. [AHA Web site]. Available at:. American Heart Association (AHA). Heart Disease and Stroke Statistics-2005 Update. Accessed (August 1, 2005). http://www.americanheart.org
3. Bonow R.O., Smaha L.A., Smith Jr. S.C., et al. World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation 106 (2002) 1602-1605
4. Martin M.J., Hulley S.B., Browner W.S., et al. Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet 2 (1986) 933-936
5. Centers for Disease Control and Prevention (CDC). State-specific cholesterol screening trends-United States, 1991-1999. MMWR Morb Mortal Wkly Rep 49 (2000) 750-755
6. Weijenberg M.P., Feskens E.J., and Kromhout D. Total and high density lipoprotein cholesterol as risk factors for coronary heart disease in elderly men during 5 years of follow-up. The Zutphen Elderly Study. Am J Epidemiol 143 (1996) 151-158
7. Casiglia E., Mazza A., Tikhonoff V., et al. Total cholesterol and mortality in the elderly. J Intern Med 254 (2003) 353-362
8. [published correction appears in Circulation. 2004;110:763]. Grundy S.M., Cleeman J.I., Merz C.N., et al., National Heart, Lung, and Blood Institute, American College of Cardiology Foundation, American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
9. Heart Protection Study Collaborative Group. MRC/ BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
10. Shepherd J., Blauw G.J., Murphy M.B., et al., PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 360 (2002) 1623-1630
11. Avezum A., Makdisse M., Spencer F., et al., GRACE Investigators. Impact of age on management and outcome of acute coronary syndrome: Observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 149 (2005) 67-73
12. Allen Maycock C.A., Muhlestein J.B., Horne B.D., et al., Intermountain Heart Collaborative Study Group. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 40 (2002) 1777-1785
13. Tran C.T., Laupacis A., Mamdani M.M., and Tu J.V. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 148 (2004) 834-841
14. Sever P.S., Dahlof B., Poulter N.R., et al., ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
15. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
16. Cannon C.P., Braunwald E., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
17. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 13-23
18. Newman C.B., Palmer G., Silbershatz H., and Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 92 (2003) 670-676
19. Bakker-Arkema R.G., Nawrocki J.W., and Black D.M. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis 149 (2000) 123-129
20. van Wissen S., Smilde T.J., Trip M.D., et al. Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 95 (2005) 264-266
21. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al., REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291 (2004) 1071-1080
22. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
23. Pitt B., Waters D., Brown W.V., et al., Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowering therapy compared with angio plasty in stable coronary artery disease. N Engl J Med 341 (1999) 70-76
24. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285 (2001) 1711-1718
25. Koren M.J., Hunninghake D.B., and ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study. J Am Coll Cardiol 44 (2004) 1772-1779
26. [EMEA Web site]. ICH Topic E6. European Agency for the Evaluation of Medicinal Products, International Conference on HarmonisationWorld Health Organization. Guideline for Good Clinical Practice. Accessed March 9, 2006 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed March 9, 2006
27. US Food and Drug Administration (FDA), Dept of Health and Human Services. COSTART:: Coding Symbols for Thesaurus of Adverse Reaction Terms. 4th ed. (1993), FDA, Washington, DC
28. Ballantyne C.M., Corsini A., Davidson M.H., et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 (2003) 553-564
29. Tobert J.A. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 62 (1988) 28J-34J
30. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al., American College of Cardiology (ACC), American Heart Association (AHA), National Heart, Lung and Blood Institute (NHLBI). ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 (2002) 567-572
31. Taylor A.J., Kent S.M., Flaherty P.J., et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106 (2002) 2055-2060
32. Stern R., Abel R., Gibson G.L., and Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. J Clin Pharmacol 37 (1997) 1062-1064
33. Abstract. Sasiela W., Szarek M., Silbershatz H., and Palmer G. An examination of atorvastatin safety when used in combination with verapamil. Evidence from 44 completed clinical trials. J Am Coll Cardiol 41 Suppl A (2003) 336A
34. Abstract 1P-0296. Sasiela W., Szarek M., Silbershatz H., and Palmer G. An examination of atorvastatin safety when used in combination with amiodarone: Evidence from 44 completed clinical trials. Atherosclerosis Suppl 4 (2003) 84
35. Serebruany V.L., Midei M.G., Malinin A.I., et al. Absence of interaction between atorvastatin or other statins and clopidogrel: Results from the interaction study. Arch Intern Med 164 (2004) 2051-2057
36. Davidson M.H., Stein E.A., Hunninghake D.B., et al., Worldwide Expanded Dose Simvastatin Study Group. Lipidaltering efficacy and safety of simvastatin 80 mg/day: Worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis 10 (2000) 253-262
37. de Lemos J.A., Blazing M.A., Wiviott S.D., et al., A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syn dromes: Phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
38. Zocor (simvastatin) [prescribing information] (June 7, 2005). http://www.zocor.com/zocor/shared/documents/english/pi.pdf
39. Wiviott S.D., Cannon C.P., Morrow D.A., et al. Can lowdensity lipoprotein be too low? The safety and efficacy of achieving very low-density lipoprotein with intensive statin therapy: PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46 (2005) 1411-1416
40. Accessed. Lipitor (atorvastatin calcium) [prescribing information] (June 7, 2005). http://www.lipitor.com/pi/default.asp
41. Damsgaard E.M., Froland A., Jorgensen O.D., and Mogensen C.E. Microalbuminuria as predictor of increased mortality in elderly people. BMJ 300 (1990) 297-300
42. Available at: www.kidney.org. National Kidney Foundation (NKF). K/DOQI Clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Accessed February 15, 2006. Am J Kidney Dis 41 Suppl 3 (2003) S1-S91